Marketplace eNewsletter Bi-Monthly | Having trouble viewing this e-mail? Click here. |
|
Pharmaceutical Sciences, Manufacturing & Marketplace Report September 25, 2013 |
From Cynthia Challener, PhD, Editor, Pharmaceutical Sciences, Manufacturing & Marketplace Report In this issue, Pfizer applies a host-cell line that combines engineered glycosylation technology and enhanced gene-expression for antibody development. Patheon advances single-use systems in fill–finish operations. GlaxoSmithKline develops flow-chemistry process to produce large quantities of a key Suzuki-Miyaura coupling reagent. Plus, the benefits of nondestructive headspace analysis and the importance of selecting the right granulation method. |
||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ![]() |
|
|
![]() |
| Subscribe | Send Feedback | Advertise With Us | Visit pharmabiomarketplace.com | |
![]() |